William Blair Begins Coverage on Structure Therapeutics (NASDAQ:GPCR)

Stock analysts at William Blair began coverage on shares of Structure Therapeutics (NASDAQ:GPCR) in a research note issued on Friday, MarketBeat reports. The firm set an “outperform” rating on the stock.

Several other equities research analysts have also weighed in on GPCR. JMP Securities reiterated a “market outperform” rating and issued a $91.00 price objective on shares of Structure Therapeutics in a research note on Wednesday, December 18th. HC Wainwright reiterated a “buy” rating and issued a $80.00 price objective on shares of Structure Therapeutics in a research note on Thursday, December 19th. Finally, Stifel Nicolaus initiated coverage on Structure Therapeutics in a research report on Wednesday, January 8th. They set a “buy” rating and a $50.00 price target on the stock. Eight analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average target price of $81.29.

Structure Therapeutics Trading Up 4.1 %

GPCR stock opened at $23.75 on Friday. Structure Therapeutics has a 1-year low of $19.61 and a 1-year high of $62.74. The firm has a market cap of $1.36 billion, a P/E ratio of -32.09 and a beta of -2.75. The business’s 50 day moving average is $26.58 and its 200-day moving average is $33.59.

Structure Therapeutics (NASDAQ:GPCR) last released its quarterly earnings data on Thursday, February 27th. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($0.23) by $0.01. Sell-side analysts forecast that Structure Therapeutics will post -0.82 EPS for the current year.

Institutional Investors Weigh In On Structure Therapeutics

A number of large investors have recently bought and sold shares of GPCR. ANTIPODES PARTNERS Ltd lifted its holdings in Structure Therapeutics by 115.0% during the 4th quarter. ANTIPODES PARTNERS Ltd now owns 1,034 shares of the company’s stock worth $28,000 after buying an additional 553 shares in the last quarter. GAMMA Investing LLC lifted its holdings in Structure Therapeutics by 4,155.6% during the 4th quarter. GAMMA Investing LLC now owns 1,149 shares of the company’s stock worth $31,000 after buying an additional 1,122 shares in the last quarter. GF Fund Management CO. LTD. acquired a new position in Structure Therapeutics during the 4th quarter worth $34,000. FNY Investment Advisers LLC acquired a new position in Structure Therapeutics during the 4th quarter worth $40,000. Finally, Assetmark Inc. lifted its holdings in Structure Therapeutics by 120.0% during the 3rd quarter. Assetmark Inc. now owns 1,318 shares of the company’s stock worth $58,000 after buying an additional 719 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.